Retraction: MicroRNA-449 suppresses proliferation of hepatoma cell lines through blockade lipid metabolic pathway related to SIRT1 (Int J Oncol (2014) 45 (2143-2152) DOI: 10.3892/ijo.2014.2596);MicroRNA-449 suppresses proliferation of hepatoma cell lines through blockade lipid metabolic pathway related to SIRT1

International Journal of Oncology

Volumn 45, Issue 5, 2014, Pages 2143-2152

  Zhang, Hongyi ^a   Feng, Zhiqiang ^a   Huang, Rui ^b,c   Xia, Zhenglin ^b,c   Xiang, Guoan ^c   Zhang, Jinqian ^b  

^a AIR FORCE GENERAL HOSPITAL   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; Lipid metabolism; MicroRNA; Proliferation; SIRT1; SREBP 1c

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; CHOLESTEROL; FATTY ACID SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LONG CHAIN FATTY ACID; MICRORNA; MICRORNA 449; SIRTUIN 1; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; UNCLASSIFIED DRUG; MIRN449 MICRORNA, HUMAN; SIRT1 PROTEIN, HUMAN; STEROL REGULATORY ELEMENT BINDING PROTEIN;

3' UNTRANSLATED REGION; ARTICLE; CARCINOGENICITY; CELL GROWTH; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DNA SYNTHESIS; DOWN REGULATION; GENE REPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; LIPOGENESIS; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MITOSIS INDEX; PROTEIN EXPRESSION; PROTEIN FUNCTION; BIOSYNTHESIS; CARCINOGENESIS; GENE EXPRESSION REGULATION; GENETICS; LIPID METABOLISM; LIVER TUMOR; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION;

CARCINOGENESIS; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIPID METABOLISM; LIVER NEOPLASMS; MICRORNAS; SIGNAL TRANSDUCTION; SIRTUIN 1; STEROL REGULATORY ELEMENT BINDING PROTEINS;

EID: 84907195200     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2023.5525     Document Type: Erratum

References (74)

1. Herold C, Reck T, Fischler P, et al: Prognosis of a large cohort of patients with hepatocellular carcinoma in a single European centre. Liver 22: 23-28, 2002.
2. Okuda K: Hepatocellular carcinoma. J Hepatol 32: 225-237, 2000.
3. Bhalla KN: Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies. J Clin Oncol 23: 3971-3993, 2005.
4. Dowman JK, Hopkins LJ, Reynolds GM, al: Development of hepatocellular carcinoma in a murine model of nonalcoholic steatohepatitis induced by use of a high-fat/fructose diet and sedentary lifestyle. Am J Pathol 184: 1550-1561, 2014.
5. Karagozian R, Derdák Z and Baffy G: Obesity-associated mechanisms of hepatocarcinogenesis. Metabolism 63: 607-617, 2014.
6. Q in H and Ruan ZH: The role of monoacylglycerol lipase (MAGL) in the cancer progress. Cell Biochem Biophys: Mar 16, 2014 (Epub ahead of print).
7. Pralhada Rao R, Vaidyanathan N, Rengasamy M, Mammen Oommen A, Somaiya N and Jagannath MR: Sphingolipid metabolic pathway: An overview of major roles played in human diseases. J Lipids 2013: 178910, 2013.
8. Lee RC, Feinbaum RL and Ambros V: The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75: 843-854, 1993.
9. Xu P, Vernooy SY, Guo M and Hay BA: The Drosophila microRNA Mir-14 suppresses cell death and is required for normal fat metabolism. Curr Biol 13: 790-795, 2003.
10. Wightman B, Ha I and Ruvkun G: Post-transcriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75: 855-862, 1993.
11. Reinhart BJ, Slack FJ, Basson M, et al: The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature 403: 901-906, 2000.
12. Brennecke J, Hipfner DR, Stark A, Russell RB and Cohen SM: Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell 113: 25-36, 2003.
13. Hatfield SD, Shcherbata HR, Fischer KA, Nakahara K, Carthew RW and Ruohola-Baker H: Stem cell division is regulated by the microRNA pathway. Nature 435: 974-978, 2005.
14. Michael MZ, O' Connor SM, van Holst Pellekaan NG, Young GP and James RJ: Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res 1: 882-891, 2003.
15. Calin GA, Sevignani C, Dumitru CD, et al: Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101: 2999-3004, 2004.
16. Iorio MV, Ferracin M, Liu CG, et al: MicroRNA gene expression deregulation inhumanbreast cancer. Cancer Res 65: 7065-7070, 2005.
17. Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005.
18. He L, Thomson JM, Hemann MT, et al: A microRNA polycistron as a potential human oncogene. Nature 435: 828-833, 2005.
19. Volinia S, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006.
20. Pekarsky Y, Santanam U, Cimmino A, et al: Tcl1 expression in chronic lymphocytic leukemia is regulated by miR-29 and miR-181. Cancer Res 66: 11590-11593, 2006.
21. Slack FJ and Weidhaas JB: MicroRNAs as a potential magic bullet in cancer. Future Oncol 2: 73-82, 2006.
22. Cimmino A, Calin GA, Fabbri M, et al: MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102: 13944-13949, 2005.
23. Johnson SM, Grosshans H, Shingara J, et al: RAS is regulated by the let-7 microRNA family. Cell 120: 635-647, 2005.
24. Takamizawa J, Konishi H, Yanagisawa K, et al: Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res 64: 3753-3756, 2004.
25. Mayr C, Hemann MT and Bartel DP: Disrupting the pairing between let-7 and Hmga2 enhances oncogenic transformation. Science 315: 1576-1579, 2007.
26. Morris JP and McManus MT: Slowing down the Ras lane: MiRNAs as tumor suppressors? Sci STKE 16: 41, 2005.
27. He L, He X, Lowe SW and Hannon GJ: MicroRNAs join the p53 network -another piece in the tumour-suppression puzzle. Nat Rev Cancer 7: 819-822, 2007.
28. Lizé M, Klimke A and Dobbelstein M: MicroRNA-449 in cell fate determination. Cell Cycle 10: 2874-2882, 2011.
29. Lizé M, Pilarski S and Dobbelstein M: E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis. Cell Death Differ 17: 452-458, 2010.
30. Hida Y, Kubo Y, Murao K and Arase S: Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch Dermatol Res 299: 103-106, 2007.
31. Yeung F, Hoberg JE, Ramsey CS, et al: Modulation of NF-kappaB-dependent transcription and cell survival by the SIRT1 deacetylase. EMBO J 23: 2369-2380, 2004.
32. Walker AK, Yang F, Jiang K, et al: Conserved role of SIRT1 orthologs in fasting-dependent inhibition of the lipid/cholesterol regulator SREBP. Genes Dev 24: 1403-1417, 2010.
33. Rodgers JT and Puigserver P: Fasting-dependent glucose and lipid metabolic response through hepatic sirtuin 1. Proc Natl Acad Sci USA 104: 12861-12866, 2007.
34. Ponugoti B, Kim DH, Xiao Z, et al: SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J Biol Chem 285: 33959-33970, 2010.
35. Truman JP, García-Barros M, Obeid LM and Hannun YA: Evolving concepts in cancer therapy through targeting sphingolipid metabolism. Biochim Biophys Acta: Dec 30, 2013 (Epub ahead of print).
36. Zhou B, Li C, Qi W, et al: Downregulation of miR-181a upregulates sirtuin-1 (SIRT1) and improves hepatic insulin sensitivity. Diabetologia 55: 2032-2043, 2012.
37. Ford J, Jiang M and Milner J: Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival. Cancer Res 65: 10457-10463, 2005.
38. Hamamoto R, Furukawa Y, Morita M, et al: SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol 6: 731-740, 2004.
39. Wang H, Liu H, Chen K, et al: SIRT1 promotes tumorigenesis of hepatocellular carcinoma through PI3K/PTEN/AKT signaling. Oncol Rep 28: 311-318, 2012.
40. Eberle D, Hegarty B, Bossard P, Ferre P and Foufelle F: SREBP transcription factors: Master regulators of lipid homeostasis. Biochimie 86: 839-848, 2004.
41. Dif N, Euthine V, Gonnet E, et al: Insulin activates human sterol-regulatory-element-binding protein-1c (SREBP-1c) promoter through SRE motifs. Biochem J 400: 179-188, 2006.
42. Guillet-Deniau I, Mieulet V, Le Lay S, et al: Sterol regulatory element binding protein-1c expression and action in rat muscles: Insulin-like effects on the control of glycolytic and lipogenic enzymes and UCP3 gene expression. Diabetes 51: 1722-1728, 2002.
43. Rome S, Lecomte V, Meugnier E, et al: Microarray analyses of SREBP-1a and SREBP-1c target genes identify new regulatory pathways in muscle. Physiol Genomics 34: 327-337, 2008.
44. Giandomenico V, Simonsson M, Gronroos E and Ericsson J: Coactivator dependent acetylation stabilizes members of the SREBP family of transcription factors. Mol Cell Biol 23: 2587-2599, 2003.
45. Calkin AC and Tontonoz P: Transcriptional integration of metabolism by the nuclear sterol-activated receptors LXR and FXR. Nat Rev Mol Cell Biol 13: 213-224, 2012.
46. Yoshikawa T, Shimano H, Amemiya-Kudo M, et al: Identification of liver X receptor-retinoid X receptor as an activator of the sterol regulatory element-binding protein 1c gene promoter. Mol Cell Biol 21: 2991-3000, 2001.
47. Repa JJ, Liang G, Ou J, et al: Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 14: 2819-2830, 2000.
48. Cozzone D, Debard C, Dif N, et al: Activation of liver X receptors promotes lipid accumulation but does not alter insulin action in human skeletal muscle cells. Diabetologia 49: 990-999, 2006.
49. Swinnen JV, Heemers H, van de Sande T, et al: Androgens, lipogenesis and prostate cancer. J Steroid Biochem Mol Biol 92: 273-279, 2004.
50. Yamashita T, Honda M, Takatori H, et al: Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. J Hepatol 50: 100-110, 2009.
51. Di Vizio D, Solomon KR and Freeman MR: Cholesterol and cholesterol-rich membranes in prostate cancer: An update. Tumori 94: 633-639, 2008.
52. Swinnen JV, Brusselmans K and Verhoeven G: Increased lipogenesis in cancer cells: New players, novel targets. Curr Opin Clin Nutr Metab Care 9: 358-365, 2006.
53. Freeman MR, Cinar B and Lu ML: Membrane rafts as potential sites of nongenomic hormonal signaling in prostate cancer. Trends Endocrinol Metab 16: 273-279, 2005.
54. Fernandez-Hernando C, Suarez Y, Rayner KJ and Moore KJ: MicroRNAs in lipid metabolism. Curr Opin Lipidol 22: 86-92, 2011.
55. Krutzfeldt J and Stoffel M: MicroRNAs: A new class of regulatory genes affecting metabolism. Cell Metab 4: 9-12, 2006.
56. Henry JC, Azevedo-Pouly AC and Schmittgen TD: MicroRNA replacement therapy for cancer. Pharm Res 28: 3030-3042, 2011.
57. Garzon R, Marcucci G and Croce CM: Targeting microRNAs in cancer: Rationale, strategies and challenges. Nat Rev Drug Discov 9: 775-789, 2010.
58. Bader AG, Brown D and Winkler M: The promise of microRNA replacement therapy. Cancer Res 70: 7027-7030, 2010.
59. Lee J and Kemper JK: Controlling SIRT1 expression by microRNAs in health and metabolic disease. Aging (Albany, NY) 2: 527-534, 2010.
60. Firestein R, Blander G, Michan S, et al: The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One 3: E2020, 2008.
61. Bae HJ, Noh JH, Kim JK, et al: MicroRNA-29c functions as a tumor suppressor by direct targeting oncogenic SIRT1 in hepatocellular carcinoma. Oncogene 33: 2557-2567, 2014.
62. Wang RH, Sengupta K, Li C, et al: Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice. Cancer Cell 14: 312-323, 2008.
63. Huffman DM, Grizzle WE, Bamman MM, et al: SIRT1 is significantly elevated in mouse and human prostate cancer. Cancer Res 67: 6612-6618, 2007.
64. Jang KY, Kim KS, Hwang SH, et al: Expression and prognostic significance of SIRT1 in ovarian epithelial tumours. Pathology 41: 366-371, 2009.
65. Cha EJ, Noh SJ, Kwon KS, et al: Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res 15: 4453-4459, 2009.
66. Stunkel W, Peh BK, Tan YC, et al: Function of the SIRT1 protein deacetylase in cancer. Biotechnol J 2: 1360-1368, 2007.
67. Chen J, Zhang B, Wong N, et al: Sirtuin 1 is upregulated in a subset of hepatocellular carcinomas where it is essential for telomere maintenance and tumor cell growth. Cancer Res 71: 4138-4149, 2011.
68. Noh JH, Jung KH, Kim JK, et al: Aberrant regulation of HDAC2 mediates proliferation of hepatocellular carcinoma cells by deregulating expression of G1/S cell cycle proteins. PLoS One 6: E28103, 2011.
69. Xie HJ, Noh JH, Kim JK, et al: HDAC1 inactivation induces mitotic defect and caspase-independent autophagic cell death in liver cancer. PLoS One 7: E34265, 2012.
70. Buurman R, Gürlevik E, Schäffer V, et al: Histone deacetylases activate hepatocyte growth factor signaling by repressing microRNA-449 in hepatocellular carcinoma cells. Gastroenterology 143: 811-820, 2012.
71. Huang WC, Li X, Liu J, Lin JT and Chung LW: Activation of androgen receptor, lipogenesis and oxidative stress converged by SREBP-1 is responsible for regulating growth and progression of prostate cancer cells. Mol Cancer Res 10: 133-142, 2012.
72. Menendez JA, Decker JP and Lupu R: In support of fatty acid synthase (FAS) as a metabolic oncogene: Extracellular acidosis acts in an epigenetic fashion activating FAS gene expression in cancer cells. J Cell Biochem 94: 1-4, 2005.
73. Baron A, Migita T, Tang D and Loda M: Fatty acid synthase: A metabolic oncogene in prostate cancer? J Cell Biochem 91: 47-53, 2004.
74. Li Y, Xu J, Chen H, et al: Comprehensive analysis of the functional microRNA-mRNA regulatory network identifies miRNA signatures associated with hepatoma malignant progression. Nucleic Acids Res 41: E203, 2013.